Interbody Spacers With map3® Cellular Allogeneic Bone Graft in Anterior or Lateral Lumbar Interbody Fusion

Completed · Not applicable

Conditions studied: Spondylosis, Spondylolisthesis, Degenerative Disc Disease

In brief

This is a single-arm post-market study in patients requiring lumbar fusion using allograft interbody spacer in conjunction with map3® Cellular Allogeneic Bone Graft in patients with degenerative disc disease (DDD). This cohort study will enroll 80 patients total at up to 10 sites. After subjects have signed an informed consent, the baseline visit and examinations will be completed. Patients will be evaluated at 6 weeks, 3 months, 6 months, 12 months, and 24 month visit after surgery.

Key facts

Study ID

NCT02628210

Run by

RTI Surgical

People needed

30

Starts

2016-02-01

Expected to finish

2020-06-01

Last updated by the study team

2021-05-24

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• is at least 18 - 75 years of age and skeletally mature
• must have symptomatic spondylosis, spondylolisthesis grade I or II, or degenerative disc disease (DDD) at one level from L2-S1 requiring a fusion
• must be a candidate to use an allograft spacer
• must be a candidate for bilateral pedicle screw placement
• must have completed a minimum of six weeks (+/- two to four weeks of bracing) of unsuccessful conservative, non-operative care
• must have discogenic back pain with or without leg pain DDD must be confirmed by MRI or CT scans followed by discography (if necessary)
• must score at least 40 % on the Oswestry Disability Index
• must score 4 or more on a 10 cm Visual Analog Scale for back pain or leg pain
• must be able to comply with the protocol's follow-up schedule
• must understand and sign the informed consent documenT

You may not qualify if…

• symptomatic at more than one level
• previous fusion surgery at any lumbar level with or without instrumentation.
• any other bone grafting product other than study product and local autograft bone. e.g. rhBMP2, (recombinant human bone morphogenetic protein 2).
• patients requiring any other interbody fusion device other than an allograft spacer (Bigfoot™, Crossfuse® Advantage). e.g. no PEEK IBF
• more than 50% spondylolisthesis (Myerding grade III or more)
• lumbar scoliosis greater than 11 degrees
• osteoporosis* (T-score of -2.5 or lower), osteomalacia, Paget's disease or --metabolic bone disease.
• spinal tumors
• active arachnoiditis
• fractures of the epiphyseal plate or fractures for which stabilization of the fracture is not possible.
• impaired calcium metabolism
• active infection or surgical site infection
• rheumatoid arthritis or other autoimmune disease that affects bone healing (at the surgeon's discretion)
• chronic steroid use except for chronic inhalers (used steroids for one month within the last 6 months) or any medical condition that requires treatment with drugs known to interfere with bone healing
• use of glucocorticoids > 10 mg/day
• systemic disease such as AIDS, HIV, hepatitis (active), tuberculosis
• morbid obesity defined as body mass index (BMI) >45 or a weight more than 100 lbs. over ideal body weight
• uncontrolled diabetes documented with an Hbg A1C >9 or insulin dependent diabetics
• smokers unless approved by Sponsor, including electronic cigarettes and vaporizers
• within the past two (2) years, psychosocial disorders that would preclude accurate evaluation or has a history of substance abuse any history or active cancer
• pregnancy, or interested in becoming pregnant while participating in the study
• participation in another investigational study within 30 days

Where it is running

• Spine Surgery of Buffalo Niagara, LLC — Niagara Falls, New York, United States
• AXIS Neurosurgery and Spine of WNY, PLLC — Williamsville, New York, United States
• Carl & Edyth Lindner Center for Research The Christ Hospital — Cincinnati, Ohio, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.